Relay Therapeutics (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 13,820 Shares of Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 13,820 shares of the stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total value of $105,308.40. Following the transaction, the chief financial officer owned 250,996 shares of the company’s stock, valued at $1,912,589.52. The trade was a 5.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Thomas Catinazzo also recently made the following trade(s):

• On Wednesday, January 28th, Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock. The shares were sold at an average price of $8.45, for a total value of $14,322.75.

Relay Therapeutics Stock Up 0.8%

NASDAQ RLAY opened at $7.71 on Friday. The company has a market cap of $1.34 billion, a PE ratio of -4.41 and a beta of 1.55. Relay Therapeutics, Inc. has a 52 week low of $1.77 and a 52 week high of $9.04. The firm’s 50-day simple moving average is $7.96 and its two-hundred day simple moving average is $5.95.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.04). As a group, equities research analysts anticipate that Relay Therapeutics, Inc. will post -2.55 EPS for the current year.

Institutional Trading of Relay Therapeutics

A number of large investors have recently modified their holdings of RLAY. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Relay Therapeutics by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock worth $71,000 after purchasing an additional 1,757 shares in the last quarter. Cresset Asset Management LLC grew its stake in Relay Therapeutics by 5.0% in the 3rd quarter. Cresset Asset Management LLC now owns 38,932 shares of the company’s stock worth $203,000 after buying an additional 1,848 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in Relay Therapeutics by 8.1% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 27,871 shares of the company’s stock worth $145,000 after buying an additional 2,079 shares in the last quarter. Prelude Capital Management LLC increased its holdings in shares of Relay Therapeutics by 18.7% in the 3rd quarter. Prelude Capital Management LLC now owns 19,700 shares of the company’s stock worth $103,000 after buying an additional 3,100 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its position in shares of Relay Therapeutics by 5.0% during the 2nd quarter. Los Angeles Capital Management LLC now owns 68,615 shares of the company’s stock valued at $237,000 after buying an additional 3,275 shares in the last quarter. Institutional investors own 96.98% of the company’s stock.

Relay Therapeutics News Summary

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Shares are trading up intraday, sitting above the 200?day moving average—a technical signal some investors view as constructive. MarketBeat RLAY quote
• Neutral Sentiment: Despite the recent sales, insiders still hold large positions (many hundreds of thousands of shares), which reduces the likelihood of a meaningful shift in strategic control; the disclosures show percentage ownership declines but substantial remaining stakes. (See SEC filings linked below.)
• Negative Sentiment: CFO Thomas Catinazzo sold 1,695 shares at an average $8.45 on Jan. 28 (total ~$14.3k), and had also sold 13,820 shares at ~$7.62 on Jan. 27; these filings show a multi-day reduction in the CFO’s ownership. Catinazzo filings
• Negative Sentiment: Insider Peter Rahmer sold 1,354 shares at $8.45 (Jan. 28) and 11,684 shares at $7.62 (Jan. 27), reducing his stake by several percent—more insider selling that can weigh on sentiment. Rahmer filings
• Negative Sentiment: Insider Donald A. Bergstrom sold 2,686 shares at $8.45 and 18,895 shares at $7.62 across Jan. 27–28, cutting his position by ~4%. Large, clustered insider sales can amplify near?term downward pressure. Bergstrom filings
• Negative Sentiment: Market commentary highlights recent weakness in RLAY (example: a note explaining a ~5.2% drop), which may reflect short?term sentiment, sector dynamics, or news-driven selling; that coverage can push momentum lower even if fundamentals are unchanged. Why RLAY is down 5.18%

Analyst Ratings Changes

A number of research firms recently issued reports on RLAY. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Oppenheimer upgraded Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price target on the stock in a research report on Monday. Finally, Wells Fargo & Company upgraded shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $6.00 to $13.00 in a research report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Relay Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $16.57.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.